Loading cancer entity…
Loading cancer entity…
Clinical trials
22 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07338968 | A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma(CoMpass) | enrolling by invitation | — | 100 | Aura BiosciencesINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06007690 | A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma(CoMpass) | active not recruiting | Phase 3 | 108 | Aura BiosciencesINDUSTRY | 14 | Jul 31, 2026 | clinicaltrials |
| NCT03941379 | A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma | active not recruiting | — | 63 | Aura BiosciencesINDUSTRY | 1 | May 22, 2026 |
Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials
| NCT07421739 | Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects | recruiting | — | 15 | Aura BiosciencesINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |